Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Protagonist Therapeutics (PTGX) Return on Sales (2017 - 2025)

Historic Return on Sales for Protagonist Therapeutics (PTGX) over the last 9 years, with Q3 2025 value amounting to 8.35%.

  • Protagonist Therapeutics' Return on Sales fell 12400.0% to 8.35% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.23%, marking a year-over-year decrease of 3200.0%. This contributed to the annual value of 0.63% for FY2024, which is 19500.0% up from last year.
  • Protagonist Therapeutics' Return on Sales amounted to 8.35% in Q3 2025, which was down 12400.0% from 6.27% recorded in Q2 2025.
  • Over the past 5 years, Protagonist Therapeutics' Return on Sales peaked at 0.81% during Q1 2024, and registered a low of 45.51% during Q2 2022.
  • Its 5-year average for Return on Sales is 5.6%, with a median of 3.29% in 2021.
  • As far as peak fluctuations go, Protagonist Therapeutics' Return on Sales plummeted by -1065400bps in 2021, and later soared by 442900bps in 2023.
  • Protagonist Therapeutics' Return on Sales (Quarter) stood at 4.31% in 2021, then surged by 93bps to 0.3% in 2022, then skyrocketed by 279bps to 0.55% in 2023, then surged by 46bps to 0.8% in 2024, then tumbled by -1146bps to 8.35% in 2025.
  • Its Return on Sales stands at 8.35% for Q3 2025, versus 6.27% for Q2 2025 and 0.41% for Q1 2025.